Survey of Ophthalmology
Volume 47 , Pages S77-S89 , August 2002

The Effect of Latanoprost Compared with Timolol in African-American, Asian, Caucasian, and Mexican Open-Angle Glaucoma or Ocular Hypertensive Patients

  • Katarina Hedman, MSc

      Affiliations

    • Corresponding Author InformationReprint address: Katarina Hedman, Pharmacia Diagnostics, S-751 82 Uppsala, Sweden
    • Department of Neuroscience—Ophthalmology, Uppsala University Hospital, Uppsala, Sweden
    • Pharmacia Diagnostics, Uppsala, Sweden
    • ,
  • Lill-Inger Larsson, MD, PhD

      Affiliations

    • Pharmacia Corporation, Stockholm, Sweden

References 

  1. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  2. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991;109:1564–1568
  3. Aquino MV, Lat-Luna M. The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension. Asian J Ophthalmol. 1999;1:3–7
  4. Blomqvist N. On the bias caused by regression toward the mean in studying the relation between change and initial value. J Clin Periodontol. 1986;13:34–37
  5. Boger WP, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 1978;85:259–267
  6. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma (a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group). Ophthalmology. 1996;103:138–147
  7. Colton T. Regression and correlation. In:  Colton T editors. Statistics in Medicine. Boston: Little Brown and Company; 1974;p. 189–217
  8. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987;105:1112–1116
  9. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402
  10. Gandolfi SA. Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1990;31:354–358
  11. Hedman K, Alm A. A pooled data analysis of three randomised, double-masked six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;2:94–104
  12. Letchinger SL, Frohlichstein D, Glieser DK, et al.  Can the concentration of timolol or the frequency of its administration be reduced?. Ophthalmology. 1993;100:1259–1262
  13. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism (Implications for uveoscleral outflow). Surv Ophthalmol. 1997;41(Suppl 2):53–59
  14. Menon IA, Trope GE, Basu PK, et al.  Binding of timolol to iris-ciliary body and melanin (an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs). J Ocul Pharmacol. 1989;5:313–324
  15. Mishima HK, Masuda K, Kitazawa Y, et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996;114:929–932
  16. Mottow-Lippa LS, Lippa EA, Naidoff MA, et al.  008% timolol ophthalmic solution. A minimal-effect dose in a normal volunteer model. Arch Ophthalmol. 1990;108:61–64
  17. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716
  18. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–191
  19. Ray WA, O'Day DM, Head WS, Robinson R. Statistical analysis for experimental models of ocular disease (continuous response measures). Curr Eye Res. 1985;4:585–597
  20. Resul B, Stjernschantz J, No K, et al.  Phenyl-substituted prostaglandins (potent and selective antiglaucoma agents). J Med Chem. 1993;36:243–248
  21. Snedecor GW, Cochran WG. Analysis of covariance. In:  Snedecor GW,  Cochran WG editor. Statistical Methods. Iowa: The Iowa State University Press; 1980;p. 365–388 7th ed,
  22. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 1992;8:691–704
  23. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  24. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension.The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  25. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358

 Supported by Pharmacia Corporation, Peapack, New Jersey, USA. Katarina Hedman is employed by Pharmacia Diagnostics, Uppsala, Sweden, and Lill-Inger Larsson is employed by Pharmacia Corporation, Stockholm, Sweden. Neither of the authors reported any proprietary interest in the development or marketing of drugs used in the clinical trials subject to this article. Presented in part at the European Society of Ophthalmology meeting in Stockholm, Sweden, June 1999 and the 6th Congress of the European Glaucoma Society, UK, London, June 2000. The authors wish to thank Adam Taube, PhD, Department of Information Science–Statistics, Uppsala University, Uppsala, Sweden; Albert Alm, MD, Department of Neuroscience–Ophthalmology, Uppsala University Hospital, Uppsala, Sweden; and Berith Ahlsten, BSc, Hospital Pharmacy, Uppsala University Hospital, Uppsala, Sweden, for valuable contributions.

PII: S0039-6257(02)00310-7

Survey of Ophthalmology
Volume 47 , Pages S77-S89 , August 2002

Article Tools

* Image Usage & Resolution